Table 2. In vitro cancer cell growth inhibiting rate of compound (5 μM) alone.

Compound (5 μM)	Inhibition rate (% of control)
	A549	HepG2	KB	MCF-7	HeLa	HCT116
6a	8.17 ± 0.50	5.46 ± 0.22	4.38 ± 2.73	1.38 ± 0.65	8.58 ± 0.34	8.60 ± 2.16
6b	—	—	—	—	—	9.26 ± 1.42
6c	6.76 ± 2.01	3.49 ± 0.30	2.16 ± 0.81	2.35 ± 0.35	7.08 ± 0.04	5.61 ± 1.32
6d	—	—	—	—	—	11.34 ± 3.27
6e	7.92 ± 2.15	13.20 ± 1.76	3.70 ± 0.81	1.86 ± 0.36	1.49 ± 0.48	20.35 ± 1.25
6f	23.77 ± 0.21	11.25 ± 3.26	2.15 ± 2.10	0.86 ± 0.10	1.07 ± 0.57	16.38 ± 1.25
6g	3.11 ± 0.15	9.45 ± 2.84	2.55 ± 3.38	3.78 ± 0.50	8.47 ± 1.71	14.86 ± 2.89
6h	6.69 ± 0.67	6.90 ± 1.65	0.43 ± 0.60	6.26 ± 0.30	10.45 ± 0.34	20.44 ± 1.46
10a	—	—	—	—	—	15.86 ± 1.02
10b	7.60 ± 0.99	11.51 ± 4.45	7.35 ± 0.81	4.65 ± 3.23	4.80 ± 0.58	17.86 ± 2.56
10c	1.44 ± 0.85	5.10 ± 1.20	2.15 ± 1.06	11.95 ± 0.42	3.55 ± 1.58	12.29 ± 2.97
13a	—	—	—	—	—	11.09 ± 0.24
13b	—	—	—	—	—	10.93 ± 2.17
13c	—	—	—	—	—	12.56 ± 1.84
Cisplatin	39.77 ± 1.01	55.09 ± 3.21	24.30 ± 3.29	7.76 ± 1.35	34.99 ± 0.16	41.12 ± 0.39